Literature DB >> 22982892

Evaluation of reliability of FISH versus brightfield dual-probe in situ hybridization (BDISH) for frontline assessment of HER2 status in breast cancer samples in a community setting: influence of poor tissue preservation.

Beatriz N Schiavon1, Bharat Jasani, Louise de Brot, José Vassallo, Aline Damascena, Julio Cirullo-Neto, José Ivanildo Neves, Fernando Augusto Soares, Helenice Gobbi, Rafael Malagoli Rocha.   

Abstract

AIMS: To evaluate the reliability of novel brightfield microscopy-based dual in situ hybridization (BDISH) methods for frontline HER2 status analysis in selected suboptimally preserved breast cancer tissue samples reflecting of the worst scenario in a community. METHODS AND
RESULTS: A total of 320 morphologically poorly preserved breast invasive ductal carcinomas from the archives of 2 tertiary institutions in Brazil were selected for a tissue microarray-based analysis. 4B5 antibody was used for immunohistochemistry. Fluorescence in situ hybridization (FISH), DuoCISH, ZytoDot CISH, and silver in situ hybridization (SISH) were performed and compared. The highest agreement was observed between SISH and FISH. In addition, SISH was easier to assess in both amplified and nonamplified cases when compared with the other chromogenic methods, due to the sharpness of its dots. DuoCISH produced false-positive results, associated with thicker ill-defined dots, causing poor distinction between nonamplification and low amplification. ZytoDot CISH showed lower sensitivity, with increased frequency of false-positive results.
CONCLUSIONS: SISH is the most reliable of the BDISH methods, with sensitivity and specificity highly comparable with FISH. It is also less deleterious than other BDISH methods, producing signals that were more distinct and therefore more readily analyzable even in poorly preserved tissue.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22982892     DOI: 10.1097/PAS.0b013e3182635987

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  3 in total

1.  Problems In Determining Her2 Status In Breast Carcinoma.

Authors:  Emel Ebru Pala; Ümit Bayol; Alp Özgüzer; Ülkü Küçük; Çağlar Yıldız Akdeniz; Özlem Sezer
Journal:  J Breast Health       Date:  2015-01-01

2.  HER2 status determination: analyzing the problems to find the solutions.

Authors:  Irene Terrenato; Ilaria Pennacchia; Simonetta Buglioni; Marcella Mottolese; Vincenzo Arena
Journal:  Medicine (Baltimore)       Date:  2015-04       Impact factor: 1.889

3.  Concomitant detection of HER2 protein and gene alterations by immunohistochemistry (IHC) and silver enhanced in situ hybridization (SISH) identifies HER2 positive breast cancer with and without gene amplification.

Authors:  Zsuzsanna Varga; Raymond R Tubbs; Holger Moch
Journal:  PLoS One       Date:  2014-08-25       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.